Nutriovia

A global study published in Chemical sense And led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in 338 adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa. They found that bitterness evaluations were diffracting depending on the ancestry for two of the five drugs and the effectiveness of certain modifiers. They also found genetic variants that explain certain population differences in the reaction to bitter tastes.

“This is the first study to compare participants from various ancestors who tasted various bitter medications,” said the first author Ha Nguyen, Phd, Carol M. Christensen Postdoctoral Fellow in Money.

More specifically, the tasting panel included five drugs with a bitter taste – Tenofovir Alafenamide (Taf; for HIV), moxifloxacin (for tuberculosis), praziquantel (for schistosomiasis, a type of worm), amodiaquine (for malaria) and propylthoriacil hyperthyroidism). Other solutions have also been tested: the TAF mixed with success (sweet, reduces bitterness) or 6-methylflavone (tasteless, reduces bitterness) and sugarosi alone.

A global study led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa.

Large differences in bitterness

Differences from great person to person in bitterness assessments have been found for all medicines in all ancestry groups. In each group, some people have evaluated the drugs at the top of the bitter scale, indicating intense bitterness, while others have considered it as low as water. Despite this wide range of responses within each group, 40% of drugs differ by the ancestry group. On average, Prop was more bitter for people of Asian ancestry than other ancestors, and the amodiaquin was more bitter for people of European descent than people of African ancestry.

The differences in bitterness of the accessories between the ancestors have confirmed the previous knowledge concerning the distribution of genetic variants of the TAS2R38 taste receptor between the different global regions. There were also differences in ancestry in the bitterness of TAF when success was added. When successful has been added as sweetener to change bitterness, it worked better for Africans than Asians.

“Our results can help guide the formulation of drugs to the wrong taste to meet the needs of those most sensitive to them,” said Nguyen.

The advantages of improving bitter

The bitterness is not always bad; It can be useful when added to products to avoid accidental poisoning. “However, bitter avoidance does not help when patients reject the drugs,” said the main author Dani Reed, PHD, Money Science Director. “According to my own experience, it can be embarrassing to explain to a doctor that I did not give my child the full dose of medicine because they refused to take it because of the taste.”

Many clinicians know that the poor palatibility of a drug is an obstacle to completion and compliance with treatment, and this non-adherence is consecutive in places with low resources where each dose of medicine is vital.

“These drugs have added ingredients like sweeteners to reduce bitterness, but often these additions are only partially effective in improving taste,” said Nguyen. “By learning the differences between people and groups, we are working on bitter blocking strategies to improve the taste of drugs for everyone so that everyone who needs them can take them more easily.”

This work was supported by the financing of the National Institutes of Health (R42 DC017693), the Gates Foundation (InV-005381), the Carol M. Christensen Postdoctoral Fellowship in Human Chemosensory Science Center; and Money Chemical Senses Center Institutional Fund.

A global study published in Chemical sense And led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in 338 adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa. They found that bitterness evaluations were diffracting depending on the ancestry for two of the five drugs and the effectiveness of certain modifiers. They also found genetic variants that explain certain population differences in the reaction to bitter tastes.

“This is the first study to compare participants from various ancestors who tasted various bitter medications,” said the first author Ha Nguyen, Phd, Carol M. Christensen Postdoctoral Fellow in Money.

More specifically, the tasting panel included five drugs with a bitter taste – Tenofovir Alafenamide (Taf; for HIV), moxifloxacin (for tuberculosis), praziquantel (for schistosomiasis, a type of worm), amodiaquine (for malaria) and propylthoriacil hyperthyroidism). Other solutions have also been tested: the TAF mixed with success (sweet, reduces bitterness) or 6-methylflavone (tasteless, reduces bitterness) and sugarosi alone.

A global study led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa.

Large differences in bitterness

Differences from great person to person in bitterness assessments have been found for all medicines in all ancestry groups. In each group, some people have evaluated the drugs at the top of the bitter scale, indicating intense bitterness, while others have considered it as low as water. Despite this wide range of responses within each group, 40% of drugs differ by the ancestry group. On average, Prop was more bitter for people of Asian ancestry than other ancestors, and the amodiaquin was more bitter for people of European descent than people of African ancestry.

The differences in bitterness of the accessories between the ancestors have confirmed the previous knowledge concerning the distribution of genetic variants of the TAS2R38 taste receptor between the different global regions. There were also differences in ancestry in the bitterness of TAF when success was added. When successful has been added as sweetener to change bitterness, it worked better for Africans than Asians.

“Our results can help guide the formulation of drugs to the wrong taste to meet the needs of those most sensitive to them,” said Nguyen.

The advantages of improving bitter

The bitterness is not always bad; It can be useful when added to products to avoid accidental poisoning. “However, bitter avoidance does not help when patients reject the drugs,” said the main author Dani Reed, PHD, Money Science Director. “According to my own experience, it can be embarrassing to explain to a doctor that I did not give my child the full dose of medicine because they refused to take it because of the taste.”

Many clinicians know that the poor palatibility of a drug is an obstacle to completion and compliance with treatment, and this non-adherence is consecutive in places with low resources where each dose of medicine is vital.

“These drugs have added ingredients like sweeteners to reduce bitterness, but often these additions are only partially effective in improving taste,” said Nguyen. “By learning the differences between people and groups, we are working on bitter blocking strategies to improve the taste of drugs for everyone so that everyone who needs them can take them more easily.”

This work was supported by the financing of the National Institutes of Health (R42 DC017693), the Gates Foundation (InV-005381), the Carol M. Christensen Postdoctoral Fellowship in Human Chemosensory Science Center; and Money Chemical Senses Center Institutional Fund.

A global study published in Chemical sense And led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in 338 adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa. They found that bitterness evaluations were diffracting depending on the ancestry for two of the five drugs and the effectiveness of certain modifiers. They also found genetic variants that explain certain population differences in the reaction to bitter tastes.

“This is the first study to compare participants from various ancestors who tasted various bitter medications,” said the first author Ha Nguyen, Phd, Carol M. Christensen Postdoctoral Fellow in Money.

More specifically, the tasting panel included five drugs with a bitter taste – Tenofovir Alafenamide (Taf; for HIV), moxifloxacin (for tuberculosis), praziquantel (for schistosomiasis, a type of worm), amodiaquine (for malaria) and propylthoriacil hyperthyroidism). Other solutions have also been tested: the TAF mixed with success (sweet, reduces bitterness) or 6-methylflavone (tasteless, reduces bitterness) and sugarosi alone.

A global study led by the Money Chemical Senses Center examined the intensity of the bitterness of five drugs and two bitter modifiers in adults of European origin and recent and Canadian immigrants from Asia, South Asia and Africa.

Large differences in bitterness

Differences from great person to person in bitterness assessments have been found for all medicines in all ancestry groups. In each group, some people have evaluated the drugs at the top of the bitter scale, indicating intense bitterness, while others have considered it as low as water. Despite this wide range of responses within each group, 40% of drugs differ by the ancestry group. On average, Prop was more bitter for people of Asian ancestry than other ancestors, and the amodiaquin was more bitter for people of European descent than people of African ancestry.

The differences in bitterness of the accessories between the ancestors have confirmed the previous knowledge concerning the distribution of genetic variants of the TAS2R38 taste receptor between the different global regions. There were also differences in ancestry in the bitterness of TAF when success was added. When successful has been added as sweetener to change bitterness, it worked better for Africans than Asians.

“Our results can help guide the formulation of drugs to the wrong taste to meet the needs of those most sensitive to them,” said Nguyen.

The advantages of improving bitter

The bitterness is not always bad; It can be useful when added to products to avoid accidental poisoning. “However, bitter avoidance does not help when patients reject the drugs,” said the main author Dani Reed, PHD, Money Science Director. “According to my own experience, it can be embarrassing to explain to a doctor that I did not give my child the full dose of medicine because they refused to take it because of the taste.”

Many clinicians know that the poor palatibility of a drug is an obstacle to completion and compliance with treatment, and this non-adherence is consecutive in places with low resources where each dose of medicine is vital.

“These drugs have added ingredients like sweeteners to reduce bitterness, but often these additions are only partially effective in improving taste,” said Nguyen. “By learning the differences between people and groups, we are working on bitter blocking strategies to improve the taste of drugs for everyone so that everyone who needs them can take them more easily.”

This work was supported by the financing of the National Institutes of Health (R42 DC017693), the Gates Foundation (InV-005381), the Carol M. Christensen Postdoctoral Fellowship in Human Chemosensory Science Center; and Money Chemical Senses Center Institutional Fund.